Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes
about
Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment optionsClinical significance of estrogen receptor β in breast and prostate cancer from biological aspectsEstrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer.Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian CancerActivation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in miceTriple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis.Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women.
P2860
Q26995549-CE2B3BE4-F1E4-4D23-9494-1F74DD6F4503Q28087001-0BF07C0A-3226-4B74-9183-3686AA78BE4BQ35975638-F1DFDFE9-71B6-4833-98F3-53A6A2429D73Q36167088-659CF722-F03A-4FEB-AED7-6CD6E1BC7A61Q36355880-DF961567-89E4-45C6-9E41-B6BABD855F37Q36544718-E1FD538F-4338-406B-8955-32553F81CBECQ37645090-759C786A-1AC1-4FC5-98C9-4AB32EB0A8C6Q38825756-1D14DC3D-38AB-4DF0-B2DF-8DBCD18050D2Q41561734-E7CC9B66-897A-4868-9D27-09F9AD86D481Q41616035-EB078EAB-4ADC-4DD3-970B-75B750433CE9Q48191288-9E4DA2F5-5E19-4368-B8A3-8C93EF7628F9Q48551091-EBD39D85-3F5E-41CC-B9F8-A3E1C8D9E558Q53693107-774BDBA4-F644-43E3-A8C3-3BE2581D3EC2
P2860
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Use of mTOR inhibitors in the ...... hat influence patient outcomes
@ast
Use of mTOR inhibitors in the ...... hat influence patient outcomes
@en
Use of mTOR inhibitors in the ...... hat influence patient outcomes
@nl
type
label
Use of mTOR inhibitors in the ...... hat influence patient outcomes
@ast
Use of mTOR inhibitors in the ...... hat influence patient outcomes
@en
Use of mTOR inhibitors in the ...... hat influence patient outcomes
@nl
prefLabel
Use of mTOR inhibitors in the ...... hat influence patient outcomes
@ast
Use of mTOR inhibitors in the ...... hat influence patient outcomes
@en
Use of mTOR inhibitors in the ...... hat influence patient outcomes
@nl
P2093
P2860
P3181
P356
P1476
Use of mTOR inhibitors in the ...... hat influence patient outcomes
@en
P2093
Andree Rorive
Guy Jerusalem
Joelle Collignon
P2860
P3181
P356
10.2147/BCTT.S38679
P407
P577
2014-01-01T00:00:00Z